SAN DIEGO and RICHLAND, Wash., May 28, 2015 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of IsoRay, Inc. (NYSE: ISR) has filed a federal securities fraud class action complaint in the U.S. District Court for the Central District of California. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934. IsoRay develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the U.S.
View this information on the law firm's Shareholder Rights Blog:
IsoRay Misrepresents Its Business Practices
According to the complaint, defendants made materially false and misleading statements regarding the success of its Cesium-131 seeds in treating lung cancer. Specifically, IsoRay issued a press release touting the on-line publication of the first major peer reviewed study showing improved results using its Cesuim-131 seeds in the treatment of lung cancer. Subsequently, TheStreet.com published an article asserting that IsoRay selectively edited findings from the published study to make its Cesium-131 product seem better than it really is to make up for the company's inability to deliver revenue growth. Over the next several days, IsoRay fell $1.84 per share, or 42%, on heavy trading volume.
IsoRay Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.
SOURCE Robbins Arroyo LLP